These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 11450899)

  • 41. [Ocular Behcet's disease: procedural aspects].
    Postelmans L; Verougstraete C; Caspers-Velu L
    Bull Soc Belge Ophtalmol; 2001; (280):7-11. PubMed ID: 11486467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
    Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
    Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Behcet's disease therapy review].
    Vidaller Palacín A; Robert Olalla J; Sanuy Jiménez B; Rufi Rigau G; Folch Civit J; Charte González A
    An Med Interna; 2002 Nov; 19(11):594-8. PubMed ID: 12522899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease.
    Stuebiger N; Koetter I; Zierhut M
    Br J Ophthalmol; 2000 Dec; 84(12):1437-8. PubMed ID: 11186866
    [No Abstract]   [Full Text] [Related]  

  • 45. What does it take to diagnose Behçet disease?
    Pandrea A; Rudinskaya A; Klein B; Krebs T
    J Clin Rheumatol; 2007 Feb; 13(1):31-4. PubMed ID: 17278947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of infliximab and other biologics in Behçet disease.
    Li J; Fernando S; Herkes G
    Intern Med J; 2014 Jan; 44(1):96-100. PubMed ID: 24450526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A brain mass in a patient with Behcet's disease: a case report.
    Alfedaghi AS; Masters Y; Mourou M; Eshak O
    J Med Case Rep; 2015 Sep; 9():209. PubMed ID: 26419933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pseudotumorous presentation of neuro-Behçet: role of the withdrawal of colchicine?].
    Vignes S; Vidailhet M; Dormont D; Soulié J; Wechsler B
    Rev Med Interne; 1998 Jan; 19(1):55-9. PubMed ID: 9775117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.
    Krause L; Turnbull JR; Torun N; Pleyer U; Zouboulis CC; Foerster MH
    Adv Exp Med Biol; 2003; 528():511-9. PubMed ID: 12918754
    [No Abstract]   [Full Text] [Related]  

  • 50. Behçet disease presenting with neurological complications immediately after conversion from conventional cyclosporin A to microemulsion formulation.
    Mitsui Y; Mitsui M; Urakami R; Kihara M; Takahashi M; Kusunoki S
    Intern Med; 2005 Feb; 44(2):149-52. PubMed ID: 15750277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s.
    Cingu AK; Onal S; Urgancioglu M; Tugal-Tutkun I
    Ocul Immunol Inflamm; 2012 Dec; 20(6):423-8. PubMed ID: 23163330
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The use of interferon alpha in Behçet disease: review of the literature.
    Kötter I; Günaydin I; Zierhut M; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):320-35. PubMed ID: 15079763
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Childhood-onset uveitis in Behçet disease:a descriptive study of 36 cases.
    Tugal-Tutkun I; Urgancioglu M
    Am J Ophthalmol; 2003 Dec; 136(6):1114-9. PubMed ID: 14644223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Loss of vision and diarrhoea.
    Grimbacher B; Wenger B; Deibert P; Ness T; Koetter I; Peter HH
    Lancet; 1997 Dec 20-27; 350(9094):1818. PubMed ID: 9428254
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease.
    Diwo E; Gueudry J; Saadoun D; Weschler B; LeHoang P; Bodaghi B
    Ocul Immunol Inflamm; 2017 Feb; 25(1):76-84. PubMed ID: 27541620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
    Kötter I; Eckstein AK; Stübiger N; Zierhut M
    Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis.
    Albayrak O; Oray M; Can F; Uludag Kirimli G; Gul A; Tugal-Tutkun I; Onal S
    Invest Ophthalmol Vis Sci; 2019 Jan; 60(1):52-63. PubMed ID: 30601931
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.
    Rotondo C; Lopalco G; Iannone F; Vitale A; Talarico R; Galeazzi M; Lapadula G; Cantarini L
    Mediators Inflamm; 2015; 2015():451675. PubMed ID: 26185360
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gadolinium-enhanced MRI in neuro-Behçet disease.
    Chi TW; Lin JC
    Kaohsiung J Med Sci; 1998 Sep; 14(9):590-2. PubMed ID: 9796204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A case study of neuro-psycho-Behçet's syndrome presenting with psychotic attack.
    Deniz O; Cayköylü A; Vural G; Albayrak Y; Temel S; Aydin I; Kuloğlu M
    Clin Neurol Neurosurg; 2009 Dec; 111(10):877-9. PubMed ID: 19647932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.